Literature DB >> 31164355

A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis.

Rui Lu1,2, Jun Wang1,2, Zhihong Ren1,2, Jiekai Yin3,4, Yinsheng Wang3,4, Ling Cai1,5, Gang Greg Wang6,2.   

Abstract

Mutation of DNA methyltransferase 3A at arginine 882 (DNMT3AR882mut) is prevalent in hematologic cancers and disorders. Recently, DNMT3AR882mut has been shown to have hypomorphic, dominant-negative, and/or gain-of-function effects on DNA methylation under different biological contexts. However, the causal role for such a multifaceted effect of DNMT3AR882mut in leukemogenesis remains undetermined. Here, we report TF-1 leukemia cells as a robust system useful for modeling the DNMT3AR882mut-dependent transformation and for dissecting the cause-effect relationship between multifaceted activities of DNMT3AR882mut and leukemic transformation. Ectopic expression of DNMT3AR882mut and not wild-type DNMT3A promoted TF-1 cell transformation characterized by cytokine-independent growth, and induces CpG hypomethylation predominantly at enhancers. This effect was dose dependent, acted synergistically with the isocitrate dehydrogenase 1 (IDH1) mutation, and resembled what was seen in human leukemia patients carrying DNMT3AR882mut. The transformation- and hypomethylation-inducing capacities of DNMT3AR882mut relied on a motif involved in heterodimerization, whereas its various chromatin-binding domains were dispensable. Mutation of the heterodimerization motif that interferes with DNMT3AR882mut binding to endogenous wild-type DNMT proteins partially reversed the CpG hypomethylation phenotype caused by DNMT3AR882mut, thus supporting a dominant-negative mechanism in cells. In mice, bromodomain inhibition repressed gene-activation events downstream of DNMT3AR882mut-induced CpG hypomethylation, thereby suppressing leukemogenesis mediated by DNMT3AR882mut. Collectively, this study reports a model system useful for studying DNMT3AR882mut, shows a requirement of the dominant-negative effect by DNMT3AR882mut for leukemogenesis, and describes an attractive strategy for the treatment of leukemias carrying DNMT3AR882mut. SIGNIFICANCE: These findings highlight a model system to study the functional impact of a hotspot mutation of DNMT3A at R882 in leukemia. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31164355      PMCID: PMC6897384          DOI: 10.1158/0008-5472.CAN-18-3275

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  50 in total

1.  Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Authors:  Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li
Journal:  Blood       Date:  2014-10-31       Impact factor: 22.113

2.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

3.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays.

Authors:  Martin J Aryee; Andrew E Jaffe; Hector Corrada-Bravo; Christine Ladd-Acosta; Andrew P Feinberg; Kasper D Hansen; Rafael A Irizarry
Journal:  Bioinformatics       Date:  2014-01-28       Impact factor: 6.937

4.  Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L.

Authors:  Michael S Kareta; Zaida M Botello; Joshua J Ennis; Christina Chou; Frédéric Chédin
Journal:  J Biol Chem       Date:  2006-07-07       Impact factor: 5.157

Review 5.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

6.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

7.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

8.  Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.

Authors:  Rui Lu; Ping Wang; Trevor Parton; Yang Zhou; Kaliopi Chrysovergis; Shira Rockowitz; Wei-Yi Chen; Omar Abdel-Wahab; Paul A Wade; Deyou Zheng; Gang Greg Wang
Journal:  Cancer Cell       Date:  2016-06-23       Impact factor: 31.743

9.  A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.

Authors:  Soo Jin Kim; Hongbo Zhao; Swanand Hardikar; Anup Kumar Singh; Margaret A Goodell; Taiping Chen
Journal:  Blood       Date:  2013-10-28       Impact factor: 22.113

10.  Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.

Authors:  Bowen Xu; Doan M On; Anqi Ma; Trevor Parton; Kyle D Konze; Samantha G Pattenden; David F Allison; Ling Cai; Shira Rockowitz; Shichong Liu; Ying Liu; Fengling Li; Masoud Vedadi; Stephen V Frye; Benjamin A Garcia; Deyou Zheng; Jian Jin; Gang Greg Wang
Journal:  Blood       Date:  2014-11-13       Impact factor: 25.476

View more
  9 in total

1.  Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation.

Authors:  Anna S Nam; Neville Dusaj; Franco Izzo; Rekha Murali; Robert M Myers; Tarek H Mouhieddine; Jesus Sotelo; Salima Benbarche; Michael Waarts; Federico Gaiti; Sabrin Tahri; Ross Levine; Omar Abdel-Wahab; Lucy A Godley; Ronan Chaligne; Irene Ghobrial; Dan A Landau
Journal:  Nat Genet       Date:  2022-09-22       Impact factor: 41.307

2.  The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.

Authors:  Tuong-Vi Nguyen; Shihua Yao; Yahong Wang; Alan Rolfe; Anand Selvaraj; Rachel Darman; Jiyuan Ke; Markus Warmuth; Peter G Smith; Nicholas A Larsen; Lihua Yu; Ping Zhu; Peter Fekkes; Frédéric H Vaillancourt; David M Bolduc
Journal:  J Biol Chem       Date:  2019-10-03       Impact factor: 5.157

Review 3.  The language of chromatin modification in human cancers.

Authors:  Shuai Zhao; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2021-05-17       Impact factor: 60.716

Review 4.  Interplay between chromatin marks in development and disease.

Authors:  Sanne M Janssen; Matthew C Lorincz
Journal:  Nat Rev Genet       Date:  2021-10-04       Impact factor: 53.242

5.  Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis.

Authors:  Min Liao; Ruiqing Chen; Yang Yang; Hanqing He; Liqian Xu; Yuxuan Jiang; Zhenxing Guo; Wei He; Hong Jiang; Jianwei Wang
Journal:  Acta Pharm Sin B       Date:  2021-09-22       Impact factor: 11.413

6.  DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.

Authors:  Majd Jawad; Michelle Afkhami; Yi Ding; Xiaohui Zhang; Peng Li; Kim Young; Mina Luqing Xu; Wei Cui; Yiqing Zhao; Stephanie Halene; Aref Al-Kali; David Viswanatha; Dong Chen; Rong He; Gang Zheng
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

Review 7.  Recent advances of IDH1 mutant inhibitor in cancer therapy.

Authors:  Wangqi Tian; Weitong Zhang; Yifan Wang; Ruyi Jin; Yuwei Wang; Hui Guo; Yuping Tang; Xiaojun Yao
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 8.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

9.  Epigenetic landscape analysis of lncRNAs in acute myeloid leukemia with DNMT3A mutations.

Authors:  Yu-Jun Dai; Fang Hu; Si-Yuan He; Yue-Ying Wang
Journal:  Ann Transl Med       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.